Capital Fund Management S.A. bought a new stake in shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) during the 2nd quarter, according to its most recent filing with the SEC. The fund bought 20,700 shares of the biopharmaceutical company’s stock, valued at approximately $130,000.

Several other institutional investors have also modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Corbus Pharmaceuticals Holdings by 6.0% during the 1st quarter. Vanguard Group Inc. now owns 1,255,429 shares of the biopharmaceutical company’s stock valued at $10,357,000 after acquiring an additional 71,419 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Corbus Pharmaceuticals Holdings by 16.5% during the 1st quarter. Geode Capital Management LLC now owns 201,177 shares of the biopharmaceutical company’s stock valued at $1,659,000 after acquiring an additional 28,492 shares in the last quarter. Creative Planning boosted its position in shares of Corbus Pharmaceuticals Holdings by 3.9% during the 2nd quarter. Creative Planning now owns 173,475 shares of the biopharmaceutical company’s stock valued at $1,093,000 after acquiring an additional 6,525 shares in the last quarter. KCG Holdings Inc. boosted its position in shares of Corbus Pharmaceuticals Holdings by 1,066.5% during the 1st quarter. KCG Holdings Inc. now owns 141,209 shares of the biopharmaceutical company’s stock valued at $1,165,000 after acquiring an additional 129,104 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Corbus Pharmaceuticals Holdings by 548.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 136,812 shares of the biopharmaceutical company’s stock valued at $862,000 after acquiring an additional 115,710 shares in the last quarter. Institutional investors and hedge funds own 31.78% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://www.watchlistnews.com/capital-fund-management-s-a-buys-new-stake-in-corbus-pharmaceuticals-holdings-inc-crbp/1577608.html.

Several analysts have recently weighed in on the stock. Cantor Fitzgerald set a $24.00 target price on shares of Corbus Pharmaceuticals Holdings and gave the company a “buy” rating in a research report on Monday, July 17th. ValuEngine lowered shares of Corbus Pharmaceuticals Holdings from a “hold” rating to a “sell” rating in a research report on Wednesday, September 13th. BidaskClub upgraded shares of Corbus Pharmaceuticals Holdings from a “strong sell” rating to a “sell” rating in a research report on Friday, August 25th. Finally, Noble Financial reissued a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a report on Wednesday, August 9th. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $20.50.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ CRBP) opened at 6.55 on Thursday. The company’s market capitalization is $328.94 million. Corbus Pharmaceuticals Holdings, Inc. has a one year low of $4.65 and a one year high of $10.78. The company’s 50-day moving average is $6.51 and its 200 day moving average is $6.90.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.04. The firm had revenue of $0.35 million for the quarter, compared to the consensus estimate of $0.50 million. Corbus Pharmaceuticals Holdings had a negative net margin of 1,001.77% and a negative return on equity of 107.10%. Analysts predict that Corbus Pharmaceuticals Holdings, Inc. will post ($0.66) EPS for the current year.

About Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Institutional Ownership by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.